Experts on Frontline Treatment of Hodgkin Lymphoma
In this segment, panelists discuss the frontline treatment of patients with Hodgkin lymphoma, and ongoing trials examining novel approaches.
In this segment, panelists discuss the frontline treatment of patients with Hodgkin lymphoma, and ongoing trials examining novel approaches.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
Patients with newly-diagnosed DLBCL receiving R-CHOP at or near full-dose intensity have improved overall survival, according to study authors.
A study of the use of precision medicine-based "radiomic" features to evaluate risk of refractory disease in early-stage Hodgkin lymphoma showed promising results.